Sharing Potassium Channel Blockers for Human African Trypanosomiasis, Leishmaniasis, and Malaria Drug Discovery

Status
On going
Start date
Asset
Pharmacokinetic/ADME evaluation of small molecule compounds (in vitro, in-life and bioanalytical)
Disease
Malaria
Leishmaniasis
Human African trypanosomiasis (HAT)
Research areas
Drug

Leishmaniasis, malaria, and human African trypanosomiasis (HAT) are among the parasitic infectious diseases that disproportionately exact a heavy toll on people living in low- and middle-income countries. Prof. Fabrice Boyom, Head of the Antimicrobial & Biocontrol Agents Unit at University of Yaoundé I, is working toward the discovery and development of novel drugs for all three diseases by targeting the parasites’ critical metabolic pathways. To support Prof. Boyom’s drug discovery research, Pfizer Inc. has agreed to provide certain potassium channel blockers.